Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Alan Alda is not only a beloved actor, producer, writer and activist, but also a skilled science communicator. Those aiming to talk effectively to the public about biotech research would do well to follow his lead.
In under three years, Deborah Dunsire transformed Millennium Pharmaceuticals from an unprofitable company to Takeda's oncology centerpiece. What's next?
Public distaste for genetically modified crops shows little sign of abating. Tony Conner thinks he's found a solution: tailor crops to be more palatable to the public.
Sidney Wolfe has been criticized as an anti-pharma zealot and thorn in the side of the US Food and Drug Administration (FDA). But his critiques and outspoken views increasingly resonate with a US public that is losing trust in the drug industry.
Charismatic FasterCures president Greg Simon is on a mission to galvanize US biomedical research—and he's starting by changing attitudes to the sharing of donated patient materials.
